Skip to main content
. Author manuscript; available in PMC: 2015 Jul 9.
Published in final edited form as: Gynecol Oncol. 2011 Oct 13;124(1):48–52. doi: 10.1016/j.ygyno.2011.09.019

Table 3.

Adverse Events (N =20)

Grade
Adverse Event 0 1 2 3 4
Leukopenia 2 0 7 10 1
Thrombocytopenia 13 4 0 3 0
Neutropenia 2 0 2 11 5
Anemia 3 10 6 1 0
Other hematologic 18 0 2 0 0
Coagulation 19 1 0 0 0
Hemorrhage 18 2 0 0 0
Nausea 3 11 6 0 0
Vomitting 7 10 3 0 0
Bilirubin 19 1 0 0 0
ALT 9 4 5 2 0
Alkaline phosphatase 19 1 0 0 0
Dermatologic 14 4 2 0 0
Infection 17 0 2 1 0
Pulmonary 15 4 1 0 0
Metabolic 8 5 4 3 0
Lymphatics 16 4 0 0 0
Pain 8 10 2 0 0
Constitutional 17 3 0 0 0
Fatigue 5 8 7 0 0
Musculoskeletal 15 4 1 0 0
Neurotoxicity 16 4 0 0 0
Peripheral neuropathy 18 2 0 0 0
Renal 19 1 0 0 0
Ocular 16 3 1 0 0
Vascular 19 0 0 1 0
Flu-like syndrome 19 0 1 0 0